Patent ID: 8268773

Claim:
A method of treating a human afflicted with multiple sclerosis (MS), the method comprising: administering to the human afflicted with MS an effective amount of an antagonist of both IL-17A and IL-17F, wherein the antagonist is selected from (i) an antibody or antibody fragment that binds to a polypeptide consisting of the amino acid sequence as shown in SEQ ID NO:3, wherein the antibody or antibody fragment is capable of inhibiting the interaction of either IL-17A or IL-17F with a polypeptide having the amino acid sequence of SEQ ID NO:2; and (ii) a soluble receptor protein comprising a polypeptide having the amino acid sequence as set forth in SEQ ID NO:3 or a fragment thereof that is capable of binding IL-17A or IL-17F; wherein the inflammatory activity of both IL-17A and IL-17F in the human is reduced.